Broad-Spectrum and Selective Serine Protease Inhibitors Prevent Expression of Platelet-Derived Growth Factor–BB and Cerebral Vasospasm After Subarachnoid Hemorrhage
- 1 July 2001
- journal article
- research article
- Published by Wolters Kluwer Health in Stroke
- Vol. 32 (7) , 1665-1672
- https://doi.org/10.1161/01.str.32.7.1665
Abstract
Background and Purpose —Plasma serine protease cascade, including the complement system and thrombin, is activated in the subarachnoid space during the acute phase after subarachnoid hemorrhage (SAH). To examine the effect of protease cascade–based inflammation and subsequent vascular repair in the development of cerebral vasospasm, we examined the effect of 2 synthetic serine protease inhibitors—FUT-175, an inhibitor of thrombin and the complement system, and argatroban, a selective inhibitor of thrombin—on the development of cerebral vasospasm in a rabbit SAH model. Methods —One hundred Japanese White male rabbits were used in the study. The SAH was simulated by a single injection of autologous arterial blood into the cisterna magna. To evaluate the development of cerebral vasospasm, the caliber of the basilar artery was measured on x-ray film before and at 2 days after SAH. Nine groups of rabbits (n=6 each) were treated with continuous intravenous injection of FUT-175 (2.5, 5, 10, or 20 mg/d), argatroban (1.25, 2.5, or 5 mg/d), or the same amount of saline (vehicle) for 48 hours, starting 40 minutes after SAH. Two days after SAH, the expression of homodimer of platelet-derived growth factor–BB (PDGF-BB) in the basilar artery was examined with immunohistochemical techniques. In 20 normal rabbits, 5 μg of recombinant PDGF-BB or vehicle was injected into the cisterna magna, and the basilar arteries were examined on angiograms for 48 hours. Results —Significant differences were observed in the caliber of the basilar arteries between the vehicle group and the groups with the 3 larger doses of FUT-175 (vehicle, 52±5.0%; 5 mg, 79±5.7%; 10 mg, 80±2.5%; 20 mg, 80±3.7%) and between the vehicle group and the groups with the 2 larger doses of argatroban (vehicle, 52±6.4%; 2.5 mg, 81±9.0%; 5 mg, 85±4.1%) ( P Conclusions —Activation of the serine protease cascade and/or thrombin after SAH was demonstrated to play an essential role in the development of cerebral vasospasm. The expression of PDGF-BB–like protein in the arterial walls correlated with the development of cerebral vasospasm. Elevated PDGF-BB level in the subarachnoid space was found to induce delayed and chronic vasoconstriction.Keywords
This publication has 35 references indexed in Scilit:
- Intrathecal Administration of Thrombin Inhibitor Ameliorates Cerebral VasospasmCerebrovascular Diseases, 2000
- The “Phoenix” ADR Database of the Drug Commission of the German Medical Profession-A Clinically Useful Approach to Optimize Evidence-Based Medicine in GermanySeminars in Thrombosis and Hemostasis, 1999
- Thrombin-induced vasospasm: Cellular signaling mechanismsSurgery, 1998
- Combination of Serine Protease Inhibitor FUT-175 and Thromboxane Synthetase Inhibitor OKY-046 Decreases Cerebral Vasospasm in Patients with Subarachnoid Hemorrhage.Neurologia medico-chirurgica, 1998
- Platelet derived growth factor and subarachnoid haemorrage: A study on cisternal cerebrospinal fluidActa Neurochirurgica, 1997
- Cerebral vasospasm caused by cisternal injection of polystyrene latex beads in rabbits is inhibited by a serine protease inhibitorSurgical Neurology, 1994
- The platelet‐derived growth factor isomers, PDGF‐AA, PDGF‐AB and PDGF‐BB, induce contraction of vascular smooth muscle cells by different intracellular mechanismsFEBS Letters, 1990
- The biology of platelet-derived growth factorCell, 1986
- Potent inhibition of thrombin by the newly synthesized arginine derivative No. 805. The importance of stereo-structure of its hydrophobic carboxamide portionBiochemical and Biophysical Research Communications, 1981
- Human complement in thrombin-mediated platelet function: uptake of the C5b-9 complex.The Journal of Experimental Medicine, 1979